September 5, 2018Diabetes Obesity and Metabolism131 citations
View Full PaperGlucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis
Structured PICO
Do GLP-1 receptor agonists reduce antipsychotic-associated body weight gain in patients with schizophrenia compared to controls?
P
Population
164 patients with schizophrenia and antipsychotic-associated body weight gain (mean age 40.0 ± 11.1 years, mean body weight 105.8 ± 20.8 kg) pooled from 3 randomized studies
I
Intervention
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a class (exenatide once-weekly in 2 studies; liraglutide once-daily in 1 study) for 16.2 ± 4.0 weeks
C
Comparator
Control
O
Outcome
Difference in body weight between GLP-1RA and control after 16.2 ± 4.0 weeks of treatmentsurrogate
GLP-1 receptor agonists significantly reduce antipsychotic-associated body weight gain and improve cardio-metabolic risk factors in patients with schizophrenia, particularly those treated with clozapine or olanzapine.
Abstract
AIMS: To evaluate if glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce antipsychotic-associated body weight gain in patients with schizophrenia, when compared to controls. MATERIALS AND METHODS: We systematically searched PubMed/EMBASE/PsycINFO/Cochrane using the search terms '(antipsychotic and GLP-1RA)'. Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed. The primary outcome was difference in body weight between GLP-1RA and control; secondary outcomes included cardio-metabolic variables and adverse drug reactions (ADRs). Multiple linear regression was conducted including sex, age, psychosis severity, metabolic variable, ADRs, and GLP-1RA agent. RESULTS: Three studies (exenatide once-weekly = 2; liraglutide once-daily = 1) provided participant-level data (n = 164, age = 40.0 ± 11.1 years, body weight = 105.8 ± 20.8 kg). After 16.2 ± 4.0 weeks of treatment, body weight loss was 3.71 kg (95% CI = 2.44-4.99 kg) greater for GLP-1RA versus control (p < 0.001), number-needed-to-treat ≥5% body weight loss = 3.8 (95% CI = 2.6-7.2). Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA. Sex, age, psychosis severity, nausea, any ADR, and GLP-1RA agent did not significantly impact outcomes. Body weight loss with GLP-1RAs was greater for clozapine/olanzapine-treated patients (n = 141) than other antipsychotics (n = 27) (4.70 kg, 95% CI = 3.13-6.27 vs. 1.5 kg, 95% CI = -1.47-4.47) (p < 0.001). Nausea was more common with GLP-1RAs than control (53.6% vs. 27.5%, p = 0.002, number-needed-to-harm = 3.8). CONCLUSION: GLP-1RAs are effective and tolerable for antipsychotic-associated body weight gain, particularly clozapine/olanzapine-treated patients. With few included patients, further studies are required before making routine use recommendations for GLP-1RAs.